Provided by Parkinson & Movement Disorder Alliance

Recognition of dementia in its earliest stages is now critical with the advent of new treatments, but diagnosis can be challenging given the variable patient presentations and numerous contributing causes (eg, Alzheimer’s, Lewy body dementia, vascular trauma, etc.). This session discusses the diagnosis and treatment of dementia, including the use of diagnostic biomarker tests and efficacy/safety of medications targeting amyloid-beta, as well as preventive strategies.    

Estimated time to complete activity: 60 minutes

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by PMD Alliance.  PMD Alliance is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physician Continuing Medical Education

PMD Alliance designates this course for a maximum of 1 AMA PRA Category 1 Credit(s)™.  

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.

Educational Objectives

After completing this activity, the participant should be better able to:

• Differentiate the clinical presentations and diagnostic pathways for common causes of dementia
• Evaluate the safety, efficacy, and clinical applicability of FDA-approved and investigational disease-modifying therapies targeting amyloid and tau proteins
• Apply personalized preventive strategies to delay cognitive decline in patients at risk for neurodegenerative disease

Faculty

Institute for Neurodegenerative Diseases 

Richard S. Isaacson, MD, is a preventive neurologist and clinician researcher in the field of Alzheimer’s prevention. He founded and directed the first Alzheimer’s Prevention Clinic (APC) in the U.S. in 2013 at Weill Cornell Medicine/NewYork-Presbyterian, where he also served as director of the neurology residency program, assistant dean of faculty development, and associate professor of neurology. Dr. Isaacson currently conducts research at the Institute for Neurodegenerative Diseases, Florida. Leveraging his clinical practice and broad background in computer science, m-Health, biotechnology, and web development, Dr. Isaacson led interwoven clinical research and technology teams at the APC. His team rigorously evaluated the effects of personalized, evidence-based multi-modal interventions on cognition, serum/radiologic biomarkers of AD, and calculated AD and cardiovascular risk. He has published novel methods for using a precision medicine approach in real-world clinical practice of risk reduction for AD, and is currently funded by the NIH to create a digital health solution for AD prevention (RetainYourBrain.com).

Before his tenure at Weill Cornell Medicine, Dr. Isaacson served as associate professor of clinical neurology, vice chair of education, and education director of the McKnight Brain Institute in the Department of Neurology at the University of Miami Miller School of Medicine. He completed his residency in neurology at Beth Israel Deaconess Medical Center/Harvard Medical School and his medical internship at Mount Sinai Medical Center in Miami Beach. Before he joined the University of Miami, he served as associate medical director of the Wien Center for Alzheimer’s disease and Memory Disorders at Mount Sinai.

Disclosure of Relevant Financial Relationships

Parkinson and Movement Disorder Alliance (PMD Alliance) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  PMD Alliance is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Richard S. Isaacson, MD
• No disclosures to report

Planners reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

• Leslie Cloud, MD
• Site investigator for research supported by Amneal and Intracellular Therapies
• Speakers’ Bureau, consultant, and/or advisory board member for Amneal

• Britt Stone, MD
• Speakers’ Bureau, consultant, and/or advisory board member for Boston Scientific

• Jason Rivera, MPH
• No disclosures to report

• Clarisse Goas, NP
• Principal or site investigator for research supported by AskBio
• Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America

• Anissa Mitchel, LCSW
• No disclosures to report

• Kelly Papesh, DNP
• Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America

• Mary Ann Chapman, PhD
• Consultant for Allergan Aesthetics

• Fernando Pagan, MD
• Site investigator for research supported by Amneal and Kyowa Kirin
• Other grant support from Medtronic
• Speakers’ Bureau, consultant, and/or advisory board member for AbbVie, Acadia, Amneal, Acorda, Kyowa Kirin, Teva, Supernus, Merz, and Neurocrine

• Yasar Torres-Yaghi, MD
• No disclosures to report

PMD Alliance has received non-CME educational funding and support from ineligible companies.  This support is not tied to continuing medical education.  These relationships have been mitigated and do not influence CME content.

All identified relevant financial relationships are thoroughly vetted and mitigated according to PMD Alliance CME Program standard operating procedures. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

This activity is supported by independent medical education grants from Merz, AbbVie, Kyowa Kirin, and Mitsubishi Tanabe Pharma America.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Request for Credit

In order to obtain your CME certificate, please follow the directions provided at the conclusion of the course.  

If you have questions regarding the certification of this activity, please contact PMD Alliance at education@pmdalliance.org